Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
Public ClinicalTrials.gov record NCT00602394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
Study identification
- NCT ID
- NCT00602394
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 38 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2003
- Primary completion
- Apr 30, 2003
- Completion
- Apr 30, 2003
- Last update posted
- Jan 22, 2018
2003
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novum Pharmaceutical Research Services, 11248 Wilcrest Green, , Houston77042 | Houston | Texas | 77042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Bipolar Disorder trials
Other public records listing Bipolar Disorder. Sorted by last update posted; newest first. Not a recommendation.
- NCT06002204: Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression Active, not recruiting
- NCT05699525: Personalized Mobile Cognitive Behavioral Therapy Application Recruiting
- NCT04622150: Effectiveness RCT of Customized Adherence Enhancement Active, not recruiting
- NCT07286175: A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) Recruiting
- NCT06226025: Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder Recruiting
- NCT07105111: A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00602394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2018 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00602394 live on ClinicalTrials.gov.